Literature DB >> 3463207

Gastroduodenal mucosal secretion of bicarbonate and mucus. Physiologic control and stimulation by prostaglandins.

G Flemström.   

Abstract

Bicarbonate secretion by the surface epithelium in the stomach and duodenum maintains a nearly neutral pH in the mucus gel adherent to the surface despite acidities as high as pH 2.0 to 3.0 in the gastric lumen and pH 1.5 to 2.0 in the duodenal lumen. This strongly suggests that the alkaline secretion, together with the mucus gel, provides a first-line of protection in the stomach, and this may be the main mechanism of defense in the duodenum. Bicarbonate secretion is increased by physiologic stimuli such as sham-feeding or the presence of acid in the lumen. Endogenous mucosal production of prostaglandins is important in mediating the response to the latter. Administration of E-type prostaglandins stimulates alkaline secretion in both the stomach and duodenum and also increases the thickness of the mucus layer adherent to the mucosa. The consequent increase in surface alkalinity most likely potentiates the mucosal resistance to luminal acid and pepsin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463207     DOI: 10.1016/s0002-9343(86)80005-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease.

Authors:  J G Penston; K G Wormsley
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

2.  Effects of aging on duodenal bicarbonate secretion.

Authors:  S W Kim; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

3.  Cyclooxygenase inhibition with indomethacin increases human duodenal mucosal response to prostaglandin E1.

Authors:  D L Hogan; M A Ballesteros; M A Koss; J I Isenberg
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

4.  Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract.

Authors:  S Parkkila; A K Parkkila; T Juvonen; H Rajaniemi
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

Review 5.  Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

Authors:  K L Goa; J P Monk
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

6.  High systemic HCO3(-) and topical 16,16-dimethyl-PGE2 protect gastric mucosa against luminal acid by enhancing its preepithelial buffer capacity.

Authors:  T Ranta-Knuuttila; H Mustonen; E Kivilaakso
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.